These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32415240)

  • 61. MACULAR ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Post Hoc Analysis of Patients With Pigment Epithelial Detachments.
    Rebhun CB; Moreira-Neto C; Gune S; Hill L; Duker JS; Waheed NK
    Retina; 2020 Feb; 40(2):266-272. PubMed ID: 31972796
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Daniel E; Pan W; Ying GS; Kim BJ; Grunwald JE; Ferris FL; Jaffe GJ; Toth CA; Martin DF; Fine SL; Maguire MG;
    Ophthalmology; 2018 Jul; 125(7):1037-1046. PubMed ID: 29454660
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.
    Schmidt-Erfurth U; Vogl WD; Jampol LM; Bogunović H
    Ophthalmology; 2020 Sep; 127(9):1211-1219. PubMed ID: 32327254
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.
    Sridhar J; Hsu J; Shahlaee A; Garg SJ; Spirn MJ; Fineman MS; Vander J
    JAMA Ophthalmol; 2016 Apr; 134(4):437-43. PubMed ID: 26914218
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
    Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Factors associated with extended remission in neovascular age-related macular degeneration on pro re nata treatment protocol.
    Lin T; Dans KC; Muftuoglu IK; Meshi A; Amador-Patarroyo MJ; Cheng L; Freeman WR
    Br J Ophthalmol; 2020 Jan; 104(1):58-63. PubMed ID: 31302628
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
    Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
    Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M; Giustolisi R; Marchiori J; Bruscolini A; Mallone F; Fameli V; Nebbioso M; Abdolrahimzadeh S
    Curr Eye Res; 2018 Mar; 43(3):391-396. PubMed ID: 29166140
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Anti-Vascular Endothelial Growth Factor Resistance in Exudative Macular Degeneration and Polypoidal Choroidal Vasculopathy.
    Kokame GT; deCarlo TE; Kaneko KN; Omizo JN; Lian R
    Ophthalmol Retina; 2019 Sep; 3(9):744-752. PubMed ID: 31511169
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
    Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Characterizing Early Residual Fluid in Neovascular Age-Related Macular Degeneration using Machine Learning in Routine Clinical Practice.
    Wu AK; Perkins SW; Singh RP
    Ophthalmol Retina; 2022 Dec; 6(12):1154-1164. PubMed ID: 35760356
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Associations of Variation in Retinal Thickness With Visual Acuity and Anatomic Outcomes in Eyes With Neovascular Age-Related Macular Degeneration Lesions Treated With Anti-Vascular Endothelial Growth Factor Agents.
    Evans RN; Reeves BC; Maguire MG; Martin DF; Muldrew A; Peto T; Rogers C; Chakravarthy U
    JAMA Ophthalmol; 2020 Oct; 138(10):1043-1051. PubMed ID: 32816002
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing.
    Mimouni M; Meshi A; Vainer I; Gershoni A; Koren T; Geffen N; Nemet AY; Segal O
    Jpn J Ophthalmol; 2018 Nov; 62(6):652-658. PubMed ID: 30269186
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
    Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
    Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
    Abdelfattah NS; Hariri AH; Al-Sheikh M; Pitetta S; Ebraheem A; Wykoff CC; Sadda SR;
    Am J Ophthalmol; 2018 Aug; 192():84-90. PubMed ID: 29763612
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Non-neovascular fluid in age-related macular degeneration: observe-and-extend regimen in a case-series study.
    Santina A; Romero-Morales V; Abraham N; Somisetty S; Fogel-Levin M; Bousquet E; Nudleman E; Sadda S; Sarraf D
    Can J Ophthalmol; 2023 Dec; 58(6):592-600. PubMed ID: 36108790
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice.
    Rieveschl NB; Song W; Li A; Conti TF; Hom GL; Tsai GJ; Conti FF; Babiuch AS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2020 Feb; 51(2):68-75. PubMed ID: 32084278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.